Ra Pharmaceuticals (NASDAQ:RARX) Upgraded at Zacks Investment Research

Ra Pharmaceuticals (NASDAQ:RARX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Other equities analysts have also recently issued reports about the stock. Leerink Swann cut shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 target price for the company. in a research note on Friday, October 11th. Robert W. Baird cut shares of Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $48.00 target price for the company. in a research note on Thursday, October 10th. BidaskClub cut shares of Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 10th. Svb Leerink cut shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their target price for the company from $38.00 to $48.00 in a research note on Friday, October 11th. Finally, BMO Capital Markets cut shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 price objective for the company. in a research note on Thursday, October 10th. One research analyst has rated the stock with a sell rating and thirteen have given a hold rating to the stock. The company has an average rating of “Hold” and an average target price of $45.36.

RARX traded down $0.03 during trading on Tuesday, hitting $46.98. 31,856 shares of the company traded hands, compared to its average volume of 793,246. The company has a market cap of $2.21 billion, a PE ratio of -22.81 and a beta of 1.46. The stock’s 50-day simple moving average is $46.92 and its two-hundred day simple moving average is $37.71. Ra Pharmaceuticals has a 1 year low of $18.06 and a 1 year high of $47.55. The company has a current ratio of 25.73, a quick ratio of 25.73 and a debt-to-equity ratio of 0.01.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its earnings results on Thursday, November 7th. The company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.05). The company had revenue of $3.00 million for the quarter. Equities analysts expect that Ra Pharmaceuticals will post -2.05 EPS for the current year.

In other news, insider Alonso Ricardo sold 2,285 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $47.08, for a total value of $107,577.80. Following the completion of the sale, the insider now owns 4,573 shares in the company, valued at approximately $215,296.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $46.66, for a total transaction of $494,362.70. Following the completion of the sale, the insider now owns 8,521 shares of the company’s stock, valued at approximately $397,589.86. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in shares of Ra Pharmaceuticals by 27.9% in the 2nd quarter. BlackRock Inc. now owns 4,059,169 shares of the company’s stock worth $122,061,000 after acquiring an additional 886,583 shares during the last quarter. State Street Corp lifted its holdings in shares of Ra Pharmaceuticals by 9.5% in the 3rd quarter. State Street Corp now owns 1,645,369 shares of the company’s stock worth $38,913,000 after acquiring an additional 142,218 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Ra Pharmaceuticals by 19.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,564,112 shares of the company’s stock worth $47,033,000 after acquiring an additional 253,966 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in shares of Ra Pharmaceuticals by 4.2% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,228,000 shares of the company’s stock worth $29,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Eagle Asset Management Inc. lifted its holdings in shares of Ra Pharmaceuticals by 63.4% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,005,884 shares of the company’s stock worth $23,789,000 after acquiring an additional 390,415 shares during the last quarter.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Hedge Funds Explained

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.